Press Releases

Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sandoz, Inc., that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the U.S. Food and Drug Administration to market a generic version of Injectafer®. Under the terms of the settlements, Vifor Pharma and American Regent will grant Mylan Labo

Rafarma Pharmaceuticals, Inc. OTC  and the Czech company “Block” signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan. The new partner of the promising project is the multinational engineering group BLOCK with a unique specialization and experience in the field of healthcare and pharmacology. The interests of Rafarma in this agreement will be represented by the compa

ProBioGen, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for its GlymaxX antibody-dependent cellular cytotoxicity (ADCC) enhancement technology. With Zymeworks' recently announced global Phase III clinical trial of zanidatamab in HER2-expressing gastroesophageal adenocarcinoma, the GlymaxX technology also reaches Phase III Clinical Development. ProBioGen completed cell line development for Zanidatamab

Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications. In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate t

GenScript Biotech Corp., a global biotechnology group, announced today that it has expanded operations in the United Kingdom with new offices and a fully functional logistics center in Oxford. The facility supports U.K. customers with fast delivery of high-quality products and services for expediting research, as well as technical support. "The U.K. biosciences sector is one of the industry's leading innovation hubs, particularly in the cell and gene therapy fields," s

Aragen Life Sciences, a global research, development, and manufacturing solutions provider (CRO/CDMO), announced that it has signed a definitive agreement to acquire Pune-based Intox Pvt. Ltd. This acquisition will expand Aragen’s end-to-end integrated discovery and development platform for the pharmaceuticals, biotechnology, animal health and agrochemicals industries. It will enable Aragen to conduct safety assessment studies from a Good Laboratory Practice (GLP)-certified fa

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced it has opened a new single-use logistics hub in Westminster, Massachusetts, to strengthen the Company's global biopharma supply chain. Located near the Company's Devens, Massachusetts, manufacturing site, the new facility serves as a center for raw material storage, quality control and di

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application (“ANDA”) for vasopressin. This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company. “We expect vasopressin to be a

Crescita Therapeutics Inc., a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC (“Egis”), a leading generic pharmaceutical company in Central Eastern Europe (the “CEE”) for the rights to Pliaglis in eight countries comprising: Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania (the “Te

Organon, a global women’s healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo’s lead candidate, FOR-6219, is an investigational, potentially first-in-class oral 17B-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor entering Phase 2 clinical development for endometriosis. Forendo’s pipeline also includes a preclinical program target